The SARS-CoV-2 virus global outbreak generated a need for fast and reliable large-scale testing to diagnose and prevent further COVID-19 transmission. One of the main bottlenecks of the PCR test was the laborious and time-consuming molecular method for viral genetic material extraction. As a solution, BioEcho developed a novel and rapid multi-well extraction protocol for viral RNA and DNA that reduces the isolation of SARS-CoV-2 nucleic acids to just a few minutes per 96 samples.
SARS-CoV-2 RNA extraction in just 2 minutes
BioEcho’s patent-pending technology is based on a single-step nucleic acid extraction method and differs from the products available on the market, which are established on a silica column that follows the bind-wash-elute principle. The cutting-edge BioEcho technology increases the throughput by reducing the time for viral genetic material extraction procedure to 2 minutes following sample preparation. Speeding up this step more than 20-fold over other extraction technologies leads to thousands of tests on COVID-19 easily achievable per day.
Agile solutions for molecular diagnostics
BioEcho’s pioneering product, EchoLUTION for viral RNA and DNA extraction 48-well or 96-well kit, has been validated by multiple diagnostic laboratories for SARS-CoV-2 detection from nasopharyngeal samples. All could significantly increase their test-throughput up to many thousands per day. BioEcho’s viral nucleic acids extraction products already cover almost 12% COVID-19 PCR tests performed in Germany and estimated 50% in Austria. Currently, BioEcho is working towards implementing precise, reproducible, and rapid, automated solutions, as well as developing new technologies for the detection of numerous pathogens.
Über die BioEcho Life Sciences GmbH
BioEcho Life Sciences is a young and innovative company active in the field of Genomic Sample Preparation – the isolation and processing of DNA and RNA. Founded by a team of former Qiagen executives, BioEcho uses their know how to overcome the limitations of common methods in molecular biology and to establish sustainable processes. Their technological solutions were unthinkable until recently. Core technologies include dramatically simplified isolation procedures for nucleic acids in a single step, which form the basis of BioEcho’s portfolio of kits for purification and processing of DNA and RNA. Applying their single-step technologies, BioEcho Life Sciences paves the way for future nucleic acid analyses as well as novel approaches in genomic research and molecular diagnostics.
Firmenkontakt und Herausgeber der Meldung:
BioEcho Life Sciences GmbH
Nattermannallee 1
50829 Köln
Telefon: +49 221 998897 0
http://www.bioecho.de/
Ansprechpartner:
Dr. Maria Salazar Rondon
Product Manager
Telefon: +49 221 998897 18
E-Mail: maria.salazar.rondon@bioecho.de
Product Manager
Telefon: +49 221 998897 18
E-Mail: maria.salazar.rondon@bioecho.de
Dr. Frank Schäfer
CBO
Telefon: +49 221 998897 11
E-Mail: frank.schaefer@bioecho.de
CBO
Telefon: +49 221 998897 11
E-Mail: frank.schaefer@bioecho.de
Weiterführende Links
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.
